SBC Medical Reports Q1 Revenue of $43M, Below Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2026
0mins
Reports Q1 revenue $43M, consensus $41.66M. CEO Yoshiyuki Aikawa said, "For Q1 of FY26, SBC Medical reported revenue of $43 million, representing a 9% year-over-year decline. This decrease was primarily attributable to a strategic structural reform implemented in April 2025, involving a revision of the franchise fee structure. Excluding this structural change, the performance of our core business remained solid. In terms of profitability, our net income margin was 26%, and our EBITDA margin remained at a high level of 43%. Looking ahead, we will continue to promote our multi-brand strategy in the aesthetic dermatology field, expand our non-aesthetic medical business, and strengthen our operational foundation in overseas markets. In addition, we will pursue opportunities in the longevity market and further enhance our services through the utilization of AI, with the goal of building a sustainable and continuously growing healthcare platform."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SBC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SBC
Wall Street analysts forecast SBC stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.990
Low
9.00
Averages
9.00
High
9.00
Current: 2.990
Low
9.00
Averages
9.00
High
9.00
About SBC
SBC Medical Group Holdings Incorporated is a management company, which owns, operates, and provides management services to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including, but not limited to, advertising and marketing needs across various platforms, staff management, booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumable's procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic’s customer rewards program, and payment tools for the franchisee clinics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Visa Partners with Brale to Explore Stablecoin Settlement
- Stablecoin Settlement Collaboration: Visa announced a partnership with Brale to explore settlement using its developed stablecoin, aiming to conduct a proof of concept through the Canton Network, which, if successful, could integrate stablecoin into Visa's settlement currency network, enhancing transaction speed and privacy.
- Positive Market Reaction: This news led to a more than 2% increase in Visa's stock price, significantly outperforming the S&P 500's 0.4% rise, indicating investor optimism regarding Visa's proactive involvement in next-generation financial solutions.
- Efficiency in Transactions: By clearing transactions instantly on the blockchain, Visa can drastically reduce idle capital and improve fund utilization, further solidifying its position as a leading payment card brand in the market.
- Future Growth Potential: Visa's stablecoin initiative aligns with its reported participation in a new stablecoin consortium, showcasing the company's forward-looking strategy in emerging financial solutions, which enhances confidence in its future profitability.
See More
Visa Partners with Stable Coin to Explore Settlement Solutions
- Stablecoin Settlement Pilot: Visa is collaborating with Brale, the developer of Stable Coin, to conduct a proof of concept for stablecoin settlements via the Canton Network, which, if successful, could significantly enhance transaction efficiency and reduce idle capital.
- Positive Market Reaction: The announcement led to a more than 2% increase in Visa's stock price, easily surpassing the S&P 500's 0.4% rise, indicating strong investor confidence in the company's future potential.
- Blockchain Technology Application: Cuy Sheffield, Visa's head of crypto, noted that stablecoin settlements demonstrate how blockchain infrastructure can improve the speed and efficiency of money movement, potentially transforming traditional banking's slow processing methods.
- Optimistic Industry Outlook: Visa's involvement in a stablecoin consortium highlights its commitment to next-generation financial solutions, further solidifying its leadership position in the payments industry and potentially providing long-term strategic advantages.
See More
SBC Medical Group to Participate in Investor Conferences
- Investor Conference Schedule: SBC Medical Group will participate in several investor conferences in May and June 2026, including Lytham Partners and Noble Capital Markets, aiming to enhance its visibility and credibility among institutional investors through webcasts and one-on-one meetings.
- Meeting Dates and Formats: The company plans to hold one-on-one meetings on May 28 and deliver a webcast presentation at the Noble Capital Markets conference on June 3, showcasing its innovations and developments in the healthcare sector, which is expected to attract more investor interest in its growth potential.
- Global Expansion Strategy: SBC Medical Group is focused on expanding its global presence in the U.S. and Asia through direct operations and medical tourism initiatives, covering various fields such as aesthetic healthcare, dermatology, and orthopedics, thereby enhancing its market competitiveness and brand influence.
- NASDAQ Listing Background: Since its listing on NASDAQ in September 2024, SBC Medical Group was included in the Russell 3000® Index in June 2025, marking an increase in its recognition in the U.S. equity market, which is anticipated to provide more opportunities for future financing and market expansion.
See More
SBC Medical Opens New Dermatology Section in Thailand
- New Business Launch: SBC Medical, in partnership with BLEZ ASIA, inaugurates a new aesthetic dermatology section at BLEZ CLINIC in Bangkok's Asok district, with services set to commence in June 2026, marking a significant milestone in the company's Thai market efforts.
- Market Opportunity: With Thailand's aesthetic healthcare market experiencing rapid growth, SBC Medical aims to leverage its collaboration with BLEZ ASIA to meet the high-quality service demands of Japanese expatriates, thereby enhancing its competitive position.
- Service Features: The new dermatology section will focus on pico laser treatments for pigmentation and spot removal, ensuring a safe and professional medical environment for Japanese expatriates, which is crucial for building customer trust.
- Strategic Expansion Plan: Following the establishment of a strong reputation in Asok, SBC Medical plans to gradually expand into the broader Thai market and across ASEAN, committed to delivering high-quality medical services that cater to local needs and create new market value.
See More
SBC Medical Group Q1 2026 Earnings Call Insights
- Revenue Decline Analysis: Total revenues for Q1 2026 were $43 million, reflecting a 9% year-over-year decline primarily due to fee structure revisions implemented in April last year, which negatively impacted franchising revenue by $6.2 million and management services revenue by $2.4 million, totaling an $8.7 million decrease, indicating challenges in revenue structure adjustments.
- Profitability Decline: Net income decreased year-over-year, partly due to a one-time life insurance gain of $8.7 million in the prior year; however, excluding the impact of fee structure revisions, underlying revenue grew by 11% year-over-year, demonstrating potential business resilience.
- AI Strategy Advancement: The company is promoting an AI initiative aimed at driving top-line growth through enhanced customer experiences while also enabling a leaner, more efficient organization, with management expressing optimism about future growth as the impact of fee structure adjustments rolls off.
- Cash Flow and Investment Priorities: Management emphasized that while the current share repurchase program is not a priority, the company has a strong cash position and plans to prioritize growth investments, particularly in seeking M&A opportunities within the competitive Japanese aesthetic market.
See More
SBC Medical Group Q1 Earnings Report
- Earnings Highlights: SBC Medical Group reported a Q1 GAAP EPS of $0.11, reflecting resilience in the current market despite a 9.1% year-over-year decline, indicating ongoing profitability amidst challenges.
- Revenue Performance: The company generated $43 million in revenue for Q1, down 9.1% year-over-year and missing market expectations by $5.87 million, highlighting challenges in revenue growth that could impact investor confidence moving forward.
- Secondary Offering Announcement: SBC Medical announced a secondary offering of 3.1 million shares by a selling stockholder, aimed at strengthening its capital structure and providing funding for future expansion, demonstrating a proactive approach to market opportunities.
- Analyst Ratings: While the Q1 GAAP EPS of $0.14 beat expectations by $0.03, the revenue of $39.57 million fell short of projections, reflecting a cautious market sentiment regarding the company's future performance and potential stock price implications.
See More
Visa Partners with Brale to Explore Stablecoin Settlement
- Stablecoin Settlement Collaboration: Visa announced a partnership with Brale to explore settlement using its developed stablecoin, aiming to conduct a proof of concept through the Canton Network, which, if successful, could integrate stablecoin into Visa's settlement currency network, enhancing transaction speed and privacy.
- Positive Market Reaction: This news led to a more than 2% increase in Visa's stock price, significantly outperforming the S&P 500's 0.4% rise, indicating investor optimism regarding Visa's proactive involvement in next-generation financial solutions.
- Efficiency in Transactions: By clearing transactions instantly on the blockchain, Visa can drastically reduce idle capital and improve fund utilization, further solidifying its position as a leading payment card brand in the market.
- Future Growth Potential: Visa's stablecoin initiative aligns with its reported participation in a new stablecoin consortium, showcasing the company's forward-looking strategy in emerging financial solutions, which enhances confidence in its future profitability.
See More
Visa Partners with Stable Coin to Explore Settlement Solutions
- Stablecoin Settlement Pilot: Visa is collaborating with Brale, the developer of Stable Coin, to conduct a proof of concept for stablecoin settlements via the Canton Network, which, if successful, could significantly enhance transaction efficiency and reduce idle capital.
- Positive Market Reaction: The announcement led to a more than 2% increase in Visa's stock price, easily surpassing the S&P 500's 0.4% rise, indicating strong investor confidence in the company's future potential.
- Blockchain Technology Application: Cuy Sheffield, Visa's head of crypto, noted that stablecoin settlements demonstrate how blockchain infrastructure can improve the speed and efficiency of money movement, potentially transforming traditional banking's slow processing methods.
- Optimistic Industry Outlook: Visa's involvement in a stablecoin consortium highlights its commitment to next-generation financial solutions, further solidifying its leadership position in the payments industry and potentially providing long-term strategic advantages.
See More
SBC Medical Group to Participate in Investor Conferences
- Investor Conference Schedule: SBC Medical Group will participate in several investor conferences in May and June 2026, including Lytham Partners and Noble Capital Markets, aiming to enhance its visibility and credibility among institutional investors through webcasts and one-on-one meetings.
- Meeting Dates and Formats: The company plans to hold one-on-one meetings on May 28 and deliver a webcast presentation at the Noble Capital Markets conference on June 3, showcasing its innovations and developments in the healthcare sector, which is expected to attract more investor interest in its growth potential.
- Global Expansion Strategy: SBC Medical Group is focused on expanding its global presence in the U.S. and Asia through direct operations and medical tourism initiatives, covering various fields such as aesthetic healthcare, dermatology, and orthopedics, thereby enhancing its market competitiveness and brand influence.
- NASDAQ Listing Background: Since its listing on NASDAQ in September 2024, SBC Medical Group was included in the Russell 3000® Index in June 2025, marking an increase in its recognition in the U.S. equity market, which is anticipated to provide more opportunities for future financing and market expansion.
See More
SBC Medical Opens New Dermatology Section in Thailand
- New Business Launch: SBC Medical, in partnership with BLEZ ASIA, inaugurates a new aesthetic dermatology section at BLEZ CLINIC in Bangkok's Asok district, with services set to commence in June 2026, marking a significant milestone in the company's Thai market efforts.
- Market Opportunity: With Thailand's aesthetic healthcare market experiencing rapid growth, SBC Medical aims to leverage its collaboration with BLEZ ASIA to meet the high-quality service demands of Japanese expatriates, thereby enhancing its competitive position.
- Service Features: The new dermatology section will focus on pico laser treatments for pigmentation and spot removal, ensuring a safe and professional medical environment for Japanese expatriates, which is crucial for building customer trust.
- Strategic Expansion Plan: Following the establishment of a strong reputation in Asok, SBC Medical plans to gradually expand into the broader Thai market and across ASEAN, committed to delivering high-quality medical services that cater to local needs and create new market value.
See More
SBC Medical Group Q1 2026 Earnings Call Insights
- Revenue Decline Analysis: Total revenues for Q1 2026 were $43 million, reflecting a 9% year-over-year decline primarily due to fee structure revisions implemented in April last year, which negatively impacted franchising revenue by $6.2 million and management services revenue by $2.4 million, totaling an $8.7 million decrease, indicating challenges in revenue structure adjustments.
- Profitability Decline: Net income decreased year-over-year, partly due to a one-time life insurance gain of $8.7 million in the prior year; however, excluding the impact of fee structure revisions, underlying revenue grew by 11% year-over-year, demonstrating potential business resilience.
- AI Strategy Advancement: The company is promoting an AI initiative aimed at driving top-line growth through enhanced customer experiences while also enabling a leaner, more efficient organization, with management expressing optimism about future growth as the impact of fee structure adjustments rolls off.
- Cash Flow and Investment Priorities: Management emphasized that while the current share repurchase program is not a priority, the company has a strong cash position and plans to prioritize growth investments, particularly in seeking M&A opportunities within the competitive Japanese aesthetic market.
See More
SBC Medical Group Q1 Earnings Report
- Earnings Highlights: SBC Medical Group reported a Q1 GAAP EPS of $0.11, reflecting resilience in the current market despite a 9.1% year-over-year decline, indicating ongoing profitability amidst challenges.
- Revenue Performance: The company generated $43 million in revenue for Q1, down 9.1% year-over-year and missing market expectations by $5.87 million, highlighting challenges in revenue growth that could impact investor confidence moving forward.
- Secondary Offering Announcement: SBC Medical announced a secondary offering of 3.1 million shares by a selling stockholder, aimed at strengthening its capital structure and providing funding for future expansion, demonstrating a proactive approach to market opportunities.
- Analyst Ratings: While the Q1 GAAP EPS of $0.14 beat expectations by $0.03, the revenue of $39.57 million fell short of projections, reflecting a cautious market sentiment regarding the company's future performance and potential stock price implications.
See More
